A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT07553299 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing different weekly doses of the oral medication ecnoglutide (VRB-101) to see which one best helps people with obesity or overweight maintain their weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2026-05 · est. completion 2026-12

Where 17 sites · United States

What this study is testing ClinicalTrials.gov NCT07553299 ↗

Description as written by the study sponsor.

The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.

Treatments tested

VRB-101 also known as Oral ecnoglutide Drug

VRB-101 tablets will be administered orally.
Placebo Drug

Placebo tablets will be administered orally.

Main thing measured	To identify the dose of VRB-101 for weight maintenance
Sponsor	Verdiva Bio Dev Limited
Conditions studied	Obesity, Overweight, Weight Maintenance
GLP-1 drugs	ecnoglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07553299 ↗